MMR vaccine

The MMR vaccine is a trivalent biologic agent composed of live attenuated strains of the measles, mumps, and rubella viruses. While primarily used for childhood immunization, it has been investigated by researchers at Assiut University as an intralesional immunotherapy for resistant or recurrent condylomata acuminata (genital warts). When injected directly into the lesions (typically 0.5 ml every 2 weeks for up to three sessions), the vaccine acts as an immunomodulator, triggering a delayed-type hypersensitivity reaction and a non-specific cell-mediated immune response. This process enhances the host's immune recognition and clearance of human papillomavirus (HPV), the causative agent of the warts. In a Phase 3 clinical trial at Assiut University involving 45 patients, intralesional MMR vaccine demonstrated a 53.3% complete clearance rate for treated warts, proving to be a safe and effective option for cases resistant to conventional therapies.

Brand names

MMR Bio-ManguinhosTríplice Viral Bio-Manguinhos

Other names

measles, mumps, and rubella vaccineintralesional MMR vaccine